Full-Time

IT Director

Manufacturing Process Intelligence

Posted on 4/8/2025

AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior

Chennai, Tamil Nadu, India

Employees are expected to work in the office a minimum of three days per week.

Category
Cybersecurity
IT Project Management
IT & Security
Required Skills
SAP Products
Requirements
  • Bachelor’s or Master’s degree in Computer Science, Information Technology, Engineering, or a related field.
  • Minimum 8 years of progressive experience in IT within manufacturing, with at least 5 years in a leadership role focusing on Manufacturing Process Intelligence and/or PAT.
  • Strong understanding of pharmaceutical manufacturing, GMP practices, and regulatory frameworks.
  • Proficiency in PAT platforms (e.g. Siemens SIPAT) and their integration with other systems where required including Historian (OSI PI, Wonderware), MES (PASX and Tulip), ERP (SAP ECC and S4), LIMS, and automation and control systems (Siemens WinCC SCADA, DeltaV DCS). Good working knowledge of modelling and calculation tools, instrumentation, OPC (various flavours), and ideally continuous manufacturing equipment from Consigma (e.g. CDC50) and Zeton.
  • Proven ability to lead global teams and handle sophisticated, large-scale projects.
  • Strong analytical mindset with the ability to troubleshoot technical challenges and deliver solutions.
  • Excellent verbal and written communication and collaborator leadership skills.
Responsibilities
  • Develop and implement the Manufacturing Process Intelligence strategy to align with AstraZeneca’s 2030 bold ambition.
  • Develop a Manufacturing Process Intelligence technology roadmap that considers and makes use of technology advancements that will benefit Operations through Manufacturing Process Intelligence processes that contribute to AstraZeneca’s goals and objectives.
  • Proactively plan Manufacturing Process Intelligence projects and programmes globally with relevant AstraZeneca sites/regions.
  • Govern the design, configuration, integration, and deployment of PAT solutions globally to ensure standardisation and enterprise efficiencies.
  • Ensure PAT solutions align with industry standard processes, regulatory requirements (e.g., FDA, GMP), and company standards.
  • Continuously evaluate system performance and see opportunities for optimisation.
  • Collaborate with multi-functional teams, including Manufacturing BPO’s, Site teams, IT, ERP teams and external vendors to develop, deliver and maintain the Manufacturing Process Intelligence strategy and PAT systems globally.
  • Collaborate with IT Business Analysts, Architects and Service Delivery teams to plan, deliver and operate PAT solutions globally.
  • Ensure all PAT implementations stay in sync with regulatory requirements and cybersecurity standards.
  • Develop and maintain SOPs related to PAT usage, data integrity, and system validation.
  • Manage the PAT program budget and ensure efficient solutions.
  • Evaluate, select, and maintain relationships with PAT vendors and third-party service providers.

AstraZeneca focuses on discovering, developing, and selling prescription medicines. The company specializes in three main areas: Oncology, which deals with cancer treatments; Cardiovascular, Renal & Metabolism, which addresses heart, kidney, and metabolic diseases; and Respiratory & Immunology, which targets lung and immune system diseases. Their products are developed through extensive research and development, followed by clinical trials and regulatory approvals before they reach the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and forming strategic partnerships to enhance drug discovery. Their goal is to advance healthcare by creating effective treatments for serious diseases and collaborating with other organizations to improve their research capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery enhances AstraZeneca's R&D efficiency and innovation.
  • Real-world evidence supports AstraZeneca's drug efficacy and safety demonstrations.
  • Personalized medicine aligns with AstraZeneca's focus on precision oncology treatments.

What critics are saying

  • Class-action lawsuit over Soliris could lead to financial penalties and reputational damage.
  • AI tool for breast cancer screening may face challenges due to minority underrepresentation.
  • Investment in Dunkirk production lines may be affected by changes in French regulations.

What makes AstraZeneca unique

  • AstraZeneca excels in oncology, cardiovascular, and respiratory therapeutic areas.
  • The A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • Open Innovation program accelerates drug discovery by sharing resources with the scientific community.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Life Sciences IP Review
Apr 17th, 2025
AstraZeneca unit faces class-action suit over alleged Soliris monopoly

AstraZeneca unit faces class-action suit over alleged soliris monopoly.

Our Health Needs
Apr 11th, 2025
Study: Racial, ethnic minorities are underrepresented in AI mammogram interpretation

In 2024, AI biotech company Owkin partnered with pharma giant AstraZeneca to develop an AI-powered tool designed to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.

Medical Update Online
Apr 11th, 2025
AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025

AstraZeneca showcases progress in immunisation and real-world evidence addressing global infectious disease burden at ESCMID Global 2025.

Cision
Apr 11th, 2025
Result Of Agm

11 April 2025Results of Annual General Meeting held on 11 April 2025AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.Resolution. Votes for. % of votes cast

Europawire
Apr 8th, 2025
AstraZeneca Unveils Breakthrough Data on Vaccines and Antibody Therapies for Infections

AstraZeneca unveils breakthrough data on vaccines and antibody therapies for infections.

INACTIVE